Form D · Biotechnology

Silverback Therapeutics, Inc.

Seattle, WA · CIK 0001671858

Offering snapshot reported Oct 6, 2020 · SEC filing

Reported sold
$85M
Offering amount: $85M
Investors reported
31
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Sep 22, 2020
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Oct 6, 2020Initial$84,999,995No comparison31SEC filing
Mar 19, 2020Initial$31,754,277No comparison16SEC filing
Sep 20, 2018Initial$12,499,994No comparison3SEC filing
Jan 8, 2018Initial$3,749No comparison1SEC filing
Feb 6, 2017Amendment$10,000,001$0vs Apr 12, 20161SEC filing
Nov 30, 2016InitialYet to sellNo comparison0SEC filing
Apr 12, 2016Initial$10,000,001No comparison1SEC filing
Apr 12, 2016Initial$200No comparison2SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-377225

Source: Form D, filed Oct 6, 2020. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Vickie L. Capps Director
Robert Hershberg Director
Saqib Islam Director
Scott Platshon Director
Jonathan Root Director
Thilo Schroeder Director
Laura Shawver Director, Executive
Peter A. Thompson Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
500 Fairview Avenue North, Suite 600
Seattle, WA, 98109